search
Back to results

HEAD-Study Optimizing the Treatment of Children With BECTS (HEAD)

Primary Purpose

Epilepsy, Rolandic

Status
Terminated
Phase
Phase 3
Locations
Germany
Study Type
Interventional
Intervention
Treatment with levetiracetam or sulthiame over a six-month period.
Sponsored by
Ludwig-Maximilians - University of Munich
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Epilepsy, Rolandic focused on measuring benign epilepsy, pediatrics, children, rolandic epilepsy, levetiracetam, sulthiame

Eligibility Criteria

6 Years - 12 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age between 6 and 12 years
  2. Weight between 15 kg and 60 kg
  3. At least two preceding seizures within the last six months before study start
  4. Typical electroencephalogram (EEG) with Rolando focus (centrotemporal spike or sharp-wave-focus)
  5. Diagnosis of BECTS
  6. Written informed consent from parents and child

Exclusion Criteria:

  1. Other forms of epilepsy (e.g. continuous spikes and waves during slow sleep [CSWS], Landau-Kleffner-syndrome)
  2. Preceding treatment with antiepileptic drugs
  3. Mental Retardation (intelligence quotient [IQ] <85)
  4. Focal neurological deficit
  5. Relevant major internistic disease (e.g. hepatopathy, nephropathy, endocrinopathy)
  6. Participation in another clinical trial within the last 30 days

Sites / Locations

  • Dr. von Haunersches Kinderspital

Outcomes

Primary Outcome Measures

To evaluate the efficacy of levetiracetam in the treatment of children with BECTS compared to sulthiame

Secondary Outcome Measures

Safety and tolerability
Cognitive effects
Efficacy on EEG pattern

Full Information

First Posted
May 8, 2007
Last Updated
January 28, 2009
Sponsor
Ludwig-Maximilians - University of Munich
search

1. Study Identification

Unique Protocol Identification Number
NCT00471744
Brief Title
HEAD-Study Optimizing the Treatment of Children With BECTS
Acronym
HEAD
Official Title
HEAD-TO-HEAD Evaluation of the Antiepileptic Drugs Levetiracetam (LEV) vs. Sulthiame (STM) in a German Multi-Centre, Doubleblind Controlled Trial in Children With Benign Epilepsy With Centro-Temporal Spikes
Study Type
Interventional

2. Study Status

Record Verification Date
January 2009
Overall Recruitment Status
Terminated
Why Stopped
low patient number after 2 years recruiting
Study Start Date
June 2006 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
July 2008 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Ludwig-Maximilians - University of Munich

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The investigators hypothesize that Levetiracetam is as effective as Sulthiame in the treatment of children with BECTS. Patients entering the HEAD-Studie are either treated with Leveitracetam or Sulthiame over a 6 months period. Patients are equally randomised to one of the two treatment regimens. Administration of medication as blinded capsules.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Epilepsy, Rolandic
Keywords
benign epilepsy, pediatrics, children, rolandic epilepsy, levetiracetam, sulthiame

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
44 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Treatment with levetiracetam or sulthiame over a six-month period.
Primary Outcome Measure Information:
Title
To evaluate the efficacy of levetiracetam in the treatment of children with BECTS compared to sulthiame
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Safety and tolerability
Time Frame
6 months
Title
Cognitive effects
Time Frame
6 months
Title
Efficacy on EEG pattern
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age between 6 and 12 years Weight between 15 kg and 60 kg At least two preceding seizures within the last six months before study start Typical electroencephalogram (EEG) with Rolando focus (centrotemporal spike or sharp-wave-focus) Diagnosis of BECTS Written informed consent from parents and child Exclusion Criteria: Other forms of epilepsy (e.g. continuous spikes and waves during slow sleep [CSWS], Landau-Kleffner-syndrome) Preceding treatment with antiepileptic drugs Mental Retardation (intelligence quotient [IQ] <85) Focal neurological deficit Relevant major internistic disease (e.g. hepatopathy, nephropathy, endocrinopathy) Participation in another clinical trial within the last 30 days
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
F Heinen, Prof.
Organizational Affiliation
Ludwigs-Maximilians-Universität München
Official's Role
Principal Investigator
Facility Information:
Facility Name
Dr. von Haunersches Kinderspital
City
München
ZIP/Postal Code
81371
Country
Germany

12. IPD Sharing Statement

Citations:
PubMed Identifier
34554571
Citation
Milburn-McNulty P, Panebianco M, Marson AG. Sulthiame monotherapy for epilepsy. Cochrane Database Syst Rev. 2021 Sep 23;9(9):CD010062. doi: 10.1002/14651858.CD010062.pub3.
Results Reference
derived

Learn more about this trial

HEAD-Study Optimizing the Treatment of Children With BECTS

We'll reach out to this number within 24 hrs